Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HUMANA INCHUM · Entity 1429 | Director | January 02, 2026 | January 05, 2026 |
| Hewlett Packard Enterprise CoHPE · Entity 2984 | Director | May 01, 2026 | May 05, 2026 |
| PFIZER INCPFE · Entity 2863 | Executive Vice President | February 26, 2022 | March 01, 2022 |
| Viatris IncVTRS · Entity 3277 | Director | March 06, 2026 | March 10, 2026 |
| Zoetis Inc.ZTS · Entity 679 | Director | August 07, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HUMANA INC
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,826 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 766 · Balance 26,826 F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,467 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 2,467 F2: Director's cash fee elected to be converted into stock units, deferred at the election of the reporting person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis (over a five-year period), exempt pursuant to Rule 16(b)-3(d)(1). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 318 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 318 F3: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). |
| Humana CommonSEC Table I · non-derivative | IndirectSee Footnote | 20,634 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,634 F4: Transferred 20,634 shares into new 2024 Grantor Retained Annuity Trust effective 4/29/24, where reporting person is the sole Trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan.
F2: Director's cash fee elected to be converted into stock units, deferred at the election of the reporting person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis (over a five-year period), exempt pursuant to Rule 16(b)-3(d)(1).
F3: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).
F4: Transferred 20,634 shares into new 2024 Grantor Retained Annuity Trust effective 4/29/24, where reporting person is the sole Trustee.
Hewlett Packard Enterprise Co
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,750 |
Reported balance
After 2026-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-01 · Grant · Acquired 8,750 · Balance 8,750 F3: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: On 05/01/26, the reporting person was granted 8,750 restricted stock units ("RSUs"), all of which will cliff vest on the earlier of 05/01/27 or the date of Issuer's 2027 Annual Stockholders Meeting. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on Issuer's common stock. The reporting person elected to defer the receipt of common stock until the termination of his service as a member of the Issuer's Board of Directors. |
| Common StockSEC Table I · non-derivative | Direct | 3,444 |
Reported balance
Holding disclosure · report date 2026-05-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,444 |
| Common StockSEC Table I · non-derivative | IndirectBy Merrill Lynch | 47,721.7622 |
Reported balance
Holding disclosure · report date 2026-05-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 47,721.7622 F1: The reporting person elected to defer the receipt of common stock until the termination of his service as a member of the Issuer's Board of Directors. F2: The number of shares in column 5 includes 144.4031 vested restricted stock unit ("RSU") dividend equivalent rights at $27.93 per RSU credited to the reporting person's account on 04/23/26. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person elected to defer the receipt of common stock until the termination of his service as a member of the Issuer's Board of Directors.
F2: The number of shares in column 5 includes 144.4031 vested restricted stock unit ("RSU") dividend equivalent rights at $27.93 per RSU credited to the reporting person's account on 04/23/26.
F3: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F4: On 05/01/26, the reporting person was granted 8,750 restricted stock units ("RSUs"), all of which will cliff vest on the earlier of 05/01/27 or the date of Issuer's 2027 Annual Stockholders Meeting. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on Issuer's common stock. The reporting person elected to defer the receipt of common stock until the termination of his service as a member of the Issuer's Board of Directors.
PFIZER INC
Report date February 26, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 555,941 |
Ending reported balance
After 2022-02-26 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-02-26 · Exercise / conversion · Acquired 127,160 · Balance 649,918 F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Row 2 · 2022-02-26 · Tax withholding · Disposed 34,607 · Balance 615,311 F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3: Price is the closing price of Pfizer common stock on February 25, 2022. Row 3 · 2022-02-26 · Tax withholding · Disposed 59,370 · Balance 555,941 F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $25.60 · Expires 2022-02-26 | Direct | 0 |
Reported balance
After 2022-02-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-26 · Exercise / conversion · Disposed 127,160 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3: Price is the closing price of Pfizer common stock on February 25, 2022.
F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
Viatris Inc
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,031 |
Ending reported balance
After 2026-03-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 25,112 · Balance 25,112 Row 2 · 2026-03-06 · Exercise / conversion · Acquired 919 · Balance 26,031 F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-06 · Exercise / conversion · Disposed 25,112 · Balance 0 F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,890 |
Reported balance
After 2026-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-06 · Grant · Acquired 15,890 · Balance 15,890 F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-06 · Exercise / conversion · Disposed 918.455 · Balance 0 F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. |
Filing footnotes · ownership attribution and instrument terms
F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026.
F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.
F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027.
Zoetis Inc.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,808 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Gift · Disposed 6,650 · Balance 14,808 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 6,650 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,650 F1: Reflects a transfer by the Reporting Person of 6,650 shares to the Frank A. D'Amelio 2-Year 2026 GRAT No. 3. F2: Shares held in the Frank A. D'Amelio 2-Year 2026 GRAT No. 3, to which the reporting person is a grantor, trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a transfer by the Reporting Person of 6,650 shares to the Frank A. D'Amelio 2-Year 2026 GRAT No. 3.
F2: Shares held in the Frank A. D'Amelio 2-Year 2026 GRAT No. 3, to which the reporting person is a grantor, trustee and beneficiary.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Catalent, Inc.
Report date December 18, 2024 · Filed December 18, 2024
Section 16 reporting ended · disclosed 2024-12-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-12-18 transaction · row 1
1 source rowRow 1 · 2024-12-18 · Disposition to issuer · Disposed 12,635 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: Includes restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration"). F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: Includes restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration").
F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2009 Filed Sep 1, 2009 20:49 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 113 | $16.70 | $1,887.10 |
DisclosureSEC source: 0000078003-09-000182 · primary_doc.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,686 Underlying: Common Stock · 113 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 14, 2009 Filed Aug 18, 2009 15:31 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 201 | $15.77 | $3,169.77 |
DisclosureSEC source: 0000078003-09-000172 · dam2115.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,573 Underlying: Common Stock · 201 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2009 Filed Aug 4, 2009 15:10 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 125 | $15.93 | $1,991.25 |
DisclosureSEC source: 0000078003-09-000164 · dam2106.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,372 Underlying: Common Stock · 125 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2009 Filed Jul 16, 2009 19:56 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 131 | $15.02 | $1,967.62 |
DisclosureSEC source: 0000078003-09-000152 · dam2098.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,247 Underlying: Common Stock · 131 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2009 Filed Jul 1, 2009 20:24 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 130 | $15.00 | $1,950.00 |
DisclosureSEC source: 0000078003-09-000137 · dam2079.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,116 Underlying: Common Stock · 130 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2009 Filed Jun 16, 2009 19:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 142 | $14.13 | $2,006.46 |
DisclosureSEC source: 0000078003-09-000125 · dam2064.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,986 Underlying: Common Stock · 142 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 29, 2009 Filed Jun 2, 2009 13:58 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 131 | $15.19 | $1,989.89 |
DisclosureSEC source: 0000078003-09-000114 · dam2049.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,844 Underlying: Common Stock · 131 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2009 Filed May 18, 2009 20:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 200 | $15.01 | $3,002.00 |
DisclosureSEC source: 0000078003-09-000104 · dam2039.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,713 Underlying: Common Stock · 200 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2009 Filed May 1, 2009 18:00 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 146 | $13.36 | $1,950.56 |
DisclosureSEC source: 0000078003-09-000093 · dam2028.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,513 Underlying: Common Stock · 146 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2009 Filed Apr 16, 2009 21:20 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 145 | $13.86 | $2,009.70 |
DisclosureSEC source: 0000078003-09-000070 · dam2006.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,367 Underlying: Common Stock · 145 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 31, 2009 Filed Apr 1, 2009 20:06 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 157 | $13.62 | $2,138.34 |
DisclosureSEC source: 0000078003-09-000057 · dam1996.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,222 Underlying: Common Stock · 157 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 13, 2009 Filed Mar 16, 2009 20:50 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 3,795 | $14.54 | $55,179.30 |
DisclosureSEC source: 0000078003-09-000043 · dam1981.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,065 Underlying: Common Stock · 3,795 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:26 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 223,881 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000078003-09-000029 · dam1966.xml · derivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,881 Underlying: Common Stock · 223,881 shares Expires 2014-02-26 F2 · derivative.exercise_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant F2 · derivative.expiration_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:26 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 119,744 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-09-000029 · dam1966.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,506 F1 · shares: The reported transaction constitutes the grant of restricted stock units. Read SEC document |
| December 31, 2008 Filed Jan 5, 2009 12:58 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 112 | $17.71 | $1,983.52 |
DisclosureSEC source: 0000078003-09-000003 · dam1944.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,214 Underlying: Common Stock · 112 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2008 Filed Dec 16, 2008 23:51 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 119 | $16.63 | $1,978.97 |
DisclosureSEC source: 0000078003-08-000310 · dam1933.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,102 Underlying: Common Stock · 119 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 26, 2008 Filed Dec 1, 2008 22:24 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 125 | $16.07 | $2,008.75 |
DisclosureSEC source: 0000078003-08-000299 · dam1922.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,983 Underlying: Common Stock · 125 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 14, 2008 Filed Nov 17, 2008 21:44 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 155 | $16.28 | $2,523.40 |
DisclosureSEC source: 0000078003-08-000288 · dam1911.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,858 Underlying: Common Stock · 155 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2008 Filed Nov 3, 2008 19:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 112 | $17.71 | $1,983.52 |
DisclosureSEC source: 0000078003-08-000270 · dam1900.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,703 Underlying: Common Stock · 112 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2008 Filed Oct 16, 2008 18:50 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 122 | $16.27 | $1,984.94 |
DisclosureSEC source: 0000078003-08-000258 · dam1888.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,591 Underlying: Common Stock · 122 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2008 Filed Oct 1, 2008 21:38 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 108 | $18.44 | $1,991.52 |
DisclosureSEC source: 0000078003-08-000247 · dam1876.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,469 Underlying: Common Stock · 108 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 26, 2008 Filed Sep 29, 2008 17:55 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 38,281 | $18.66 | $714,323.46 |
DisclosureSEC source: 0000078003-08-000237 · dam1868.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,234 Read SEC document |
| September 15, 2008 Filed Sep 16, 2008 17:59 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 110 | $18.05 | $1,985.50 |
DisclosureSEC source: 0000078003-08-000228 · dam1859.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361 Underlying: Common Stock · 110 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 29, 2008 Filed Sep 2, 2008 20:22 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 105 | $19.11 | $2,006.55 |
DisclosureSEC source: 0000078003-08-000217 · dam1848.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,251 Underlying: Common Stock · 105 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2008 Filed Aug 19, 2008 16:27 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 115 | $19.97 | $2,296.55 |
DisclosureSEC source: 0000078003-08-000202 · dam1835.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,146 Underlying: Common Stock · 115 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2008 Filed Aug 1, 2008 21:10 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 107 | $18.67 | $1,997.69 |
DisclosureSEC source: 0000078003-08-000185 · dam1822.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031 Underlying: Common Stock · 107 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2008 Filed Jul 16, 2008 18:25 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 112 | $17.58 | $1,968.96 |
DisclosureSEC source: 0000078003-08-000173 · dam1811.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924 Underlying: Common Stock · 112 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2008 Filed Jul 1, 2008 20:09 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 114 | $17.47 | $1,991.58 |
DisclosureSEC source: 0000078003-08-000163 · dam1801.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 812 Underlying: Common Stock · 114 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 13, 2008 Filed Jun 16, 2008 20:34 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 111 | $17.99 | $1,996.89 |
DisclosureSEC source: 0000078003-08-000132 · dam1783.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698 Underlying: Common Stock · 111 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 30, 2008 Filed Jun 3, 2008 13:51 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 102 | $19.36 | $1,974.72 |
DisclosureSEC source: 0000078003-08-000118 · dam1767.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587 Underlying: Common Stock · 102 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2008 Filed May 16, 2008 18:06 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 105 | $20.08 | $2,108.40 |
DisclosureSEC source: 0000078003-08-000108 · dam1755.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485 Underlying: Common Stock · 105 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2008 Filed May 1, 2008 21:59 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 99 | $20.11 | $1,990.89 |
DisclosureSEC source: 0000078003-08-000091 · dam1744.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380 Underlying: Common Stock · 99 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2008 Filed Apr 17, 2008 19:30 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 96 | $20.71 | $1,988.16 |
DisclosureSEC source: 0000078003-08-000066 · dam1718.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281 Underlying: Common Stock · 96 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 31, 2008 Filed Apr 1, 2008 22:33 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 92 | $20.93 | $1,925.56 |
DisclosureSEC source: 0000078003-08-000055 · dam1708.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185 Underlying: Common Stock · 92 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 14, 2008 Filed Mar 18, 2008 18:10 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 93 | $20.64 | $1,919.52 |
DisclosureSEC source: 0000078003-08-000040 · dam1691.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93 Underlying: Common Stock · 93 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 28, 2008 Filed Mar 4, 2008 01:04 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 168,739 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0000078003-08-000025 · dam1675.xml · derivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,739 Underlying: Common Stock · 168,739 shares Expires 2013-02-28 F2 · derivative.exercise_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant F2 · derivative.expiration_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant Read SEC document |
| February 28, 2008 Filed Mar 4, 2008 01:04 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 41,703 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-08-000025 · dam1675.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,345 F1 · shares: The reported transaction constitutes the grant of restricted stock units. Read SEC document |
| September 28, 2007 Filed Oct 2, 2007 19:33 UTC | PFIZER INC PFE · Entity 2863 | GrantEmployee Stock Option (right to buy) · Derivative | 292,000 | $0.00 Strike: $24.43 | $0.00 |
DisclosureSEC source: 0000078003-07-000272 · dam1606.xml · derivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,000 Underlying: Common Stock · 292,000 shares Expires 2017-09-27 F2 · derivative.exercise_date: One-third of these stock options will vest on each of the first three anniversaries of the grant date if Mr. D'Amelio is employed by the Company on such vesting day. F2 · derivative.underlying: One-third of these stock options will vest on each of the first three anniversaries of the grant date if Mr. D'Amelio is employed by the Company on such vesting day. Read SEC document |
| September 28, 2007 Filed Oct 2, 2007 19:33 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 233,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-07-000272 · dam1606.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,280 F1 · shares: The reported transaction constitutes the grant of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.